The "Global Cell Signaling Market" is predicted to reach at a high CAGR during the forecast period (2022-2029).
Cell signaling refers to the communication processes that trigger cellular activities and coordinate cellular actions. Irregularities and errors in cell signaling are responsible for diseases like cancer, and many other autoimmune diseases, like diabetes. Cell signaling is a major field in modern medical practice and diagnosis.
Source: DataM Intelligence Analysis (2020)
The Cell Signaling market growth is driven by the increasing incidence of chronic diseases, growing funding for cell-based research, and technological advancements in cell-based research instruments.
Growing funding from the governments and private-agencies for cell-based research, is expected to drive the global cell signaling market growth.
Cell-based research such as cell signaling, stem cell research gain importance due to the increasing support from government and various private agencies across the world. For instance, according to the data available on the National Institutes of Health (NIH) portal, an estimated USD 1,626 million was granted for stem cell research in 2017. In contrast, the actual fund grants for stem cell research in 2018 amounted to USD 1,748 million.
Similar increments in funding grants were observed for research in embryonic stem cells and induced pluripotent stem cells. Similar positive trends in the increment of fund grants have been observed in the European Union for cell-based research. Consequently, the increasing participation of the government in the development of cell-based research, in the form of incremental funding, is expected to drive the growth of the market.
Increasing incidence of chronic diseases, is expected to drive the global cell signaling market growth.
The growing prevalence of these chronic diseases worldwide is driving the market to grow. For instance, according to International Diabetes Federation (IDF), in 2019, approximately 463 people were living with diabetes, and it is estimated that the number is anticipated to grow to 700 million by 2045. Cancer is a leading cause of burden globally. According to the World Health Organization (WHO), worldwide death stats of cancer is projected to reach over 13 million by 2030.
Ethical issues related to embryonic stem cell signaling research is likely to hamper the market growth
Stem cell research offers great promise for understanding basic mechanisms of human development and differentiation and the hope for new treatments for diseases such as diabetes, spinal cord injury, Parkinson’s disease, and myocardial infarction. However, human stem cell (hSC) research also raises sharp ethical and political controversies. The derivation of pluripotent stem cell lines from oocytes and embryos is fraught with disputes about the onset of human personhood and human reproduction. Ethical issues are arising at different phases of stem cell research, include
These ethical and policy issues related to embryonic stem cell signaling research are hampering the market growth.
Supply Chain Analysis
COVID-19 Impact Analysis
The COVID-19 pandemic is likely to have a profound impact on the cell signaling market. A new study published in the journal News Medical, "SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells," in October 2020, stated that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus without the rest of the viral components. As this signaling mechanism is potentially linked to worse outcomes in this situation, these findings could indicate new targets for the development of therapeutic agents. Thus, the high utility of cell signaling models for research about COVID-19 and respiratory diseases is expected to offer major growth opportunities to the market.
The endocrine signaling segment is expected to hold largest share in this market segment
Endocrine signaling occurs when cells located in different organs need to communicate, such as when the pituitary gland communicates with the kidneys. When this happens, hormones, the signaling ligands, use the bloodstream to reach their target cells. Because of their form of transport, hormones get diluted and are present in low concentrations when they act on their target cells. This is different from paracrine signaling, in which local concentrations of ligands can be very high. They have a longer-lasting effect.
The AKT Signaling Pathway segment is expected to hold largest share in this market segment
The AKT signaling pathway, also known as the survival pathway, is responsible for the increased proliferation, loss of apoptosis signaling, and cell growth. The AKT signaling pathway is the most commonly dysregulated in the most prevalent forms of cancer. Many drugs have been designed based on the rationale for inhibiting the AKT pathway, which could help achieve therapeutic results. Many drugs based on AKT signaling are currently in various stages of clinical trials.
In the treatment of advanced-stage COVID-19 patients, AKT is found as a potential therapeutic target. Its inhibition will potentially suppress the cytokine storm, fibroproliferation, pathological inflammation, and platelet activation associated with COVID-19. It also promotes resolution and prevents scarring in injured lungs. As per the study published "AKT a viable option to treat advanced-stage COVID-19 patients" in 2020, pharmacological inhibition of AKT has also been reported to inhibit angiotensin-converting enzyme 2 (ACE2) expression, a receptor for the virus entry into the lung cells, and targeting AKT for COVID-19 looks like a viable option.
AKT inhibitors can be classified into four categories. The first category consists of competitive inhibitors of the ATP binding site on the kinase domain. The second category is allosteric inhibitors of the AKT kinase domain. Other similar categories of the drug exist, which are based on the regulation of the AKT pathway. Overall, the market for the AKT signaling pathway has the largest share due to the comprehensive list of pipeline drugs, which are based on the regulation of AKT signaling.
Over the forecast period, this market is expected to grow, as commercial diagnostic tests are expected to emerge based on down-regulation of the AKT pathway.
The Flow Cytometry segment is expected to hold largest share in this market segment
Flow cytometry is a technology that provides rapid multi-parametric analysis of single cells in solution. It is very effective for the study of the immune system and its response to infectious diseases and cancer. This technology allows the researchers to trace the live movements.
The Research application segment is expected to hold largest share in this market segment
Cell signaling application in Research is major revenue generating segment due to factors such as increasing prevalence of various cancers, increase in use of cell signaling techniques in cancer research and in drug discovery. For instance, in 2019, A Phase II Study of TAS-117 in Advanced Solid Tumors with PI3K/AKT Gene Aberration completed by Minkyu Jung, Yonsei University.
Source: DataM Intelligence Analysis (2020)
North America region holds the largest market share of global Cell Signaling Market
North America is found to hold a major share of the cell signaling market and is expected to show a similar trend over the forecast period, without significant fluctuations. The cell signaling market is expected to witness numerous growth opportunities during the pandemic, with cell signaling pathways being utilized as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2. Most of the major players have been involved in R&D activities regarding cell signaling pathways. The mortality in most COVID-19 patients is due to the presence of a cytokine storm induced by the virus. The excessive production of these proinflammatory cytokines leads to acute respiratory distress syndrome aggravation and widespread tissue damage, which results in multi-organ failure and death. Thus, targeting cell signaling pathways such as cytokines during the management of COVID-19 may lead to the reduction of the mortality rate and improved outcomes. This is likely to have a positive impact on the market studied.
In the United States, for the fiscal year 2018, USD 520 million was granted by the federal government for the National Cancer Institute (NCI) budget for breast cancer research, USD 212 million for colorectal cancer research, and USD 241 million for leukemia. Additionally, the estimates available on the National Institute of Health Portal for stem cell-based research indicate a cumulative funding budget of more than USD 3 billion for research in various fields of stem cell applications. The need for cell signaling in cancer research plays a vital role in the progressive growth of the cell signaling market in the United States. The growing funding in cancer research and stem cell research are directly causing an increase in cell signaling research, particularly in the United States. The increasing trend of increment in research funding is expected to lead to the growth of the market studied in the United States.
Source: DataM Intelligence Analysis (2020)
The global Cell signaling market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Beckman Coulter Inc. (Danaher), Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., Merck KGaA, PerkinElmer Inc., Promega Corporation, Qiagen NV, and Thermo Fischer Scientific Inc, Beijing Boshumei Biotechnology Co., Ltd (PRC), RayBiotech Life, Inc. (PRC), Novus Biologicals, LLC (PRC), Xiamen Life Interconnect Technology Co., Ltd. (PRC). The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in 2020, Beckman Coulter Life Sciences launched the DxFLEX, Europe’s first CE-IVD, 13-color clinical flow cytometry system. The sensitivity and resolution of the DxFLEX expand laboratory testing capabilities, especially those focusing on user-defined assays.
Cell signaling Market Key Companies to Watch
Thermo Fisher Scientific Inc
Overview: Thermo Fisher Scientific Inc is a world leader in serving science, with annual revenue exceeding $30 billion. Company mission is to enable our customers to make the world healthier, cleaner and safer. Whether their customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, they are here to support. There global team of more than 80,000 employees delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
Product Portfolio: The Company’s portfolio comprised of include genomic solutions across a wide range of technologies, including next-generation sequencing (NGS), real-time PCR, Sanger sequencing, and microarrays.
Key Developments: In 2020, Thermo Scientific launched High-Resolution Mass Spectrometer. The new High-Resolution Mass Spectrometer redefines productivity in characterization, identification, and quantitation in unknown small molecule and peptide mapping applications.
The global Cell Signaling Market report would provide an access to an approx. 61 market data table, 52 figures and 180 pages.
Get your free sample proposal with a single click!